MUMBAI (Reuters) - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries’ (SUN.NS) $3.2 billion bid to buy Ranbaxy Laboratories (RANB.NS), but ordered the firms to divest seven products to ensure the deal doesn’t harm competition.
Sun Pharma agreed to buy Ranbaxy from Japan’s Daiichi Sankyo Co (4568.T) in April in a deal that would create India’s largest, and the world’s fifth-largest maker of generic drugs.
CCI said on Monday that it had decided that the “adverse effect of the proposed combination on competition can be eliminated by suitable modifications,” putting the companies a step closer to completing the deal.
The deal is now awaiting approvals from the U.S. Federal Trade Commission and Indian courts.
The CCI, which focused its investigation on 49 products to gauge the deal’s impact on competition, said Sun Pharma will divest all products containing tamsulosin, used to treat prostate conditions, and tolterodine, which is a treatment for incontinence.
The combined market share of the two companies for these products is 90-95 percent resulting in “near monopoly” in the market, the antitrust regulator said in its order.
It also asked Ranbaxy to divest all products marketed under six different brand names and said it would appoint an independent monitoring agency to supervise the changes. The companies have six months to comply.
Sun Pharma and Ranbaxy said in separate statements to the stock exchanges that the seven products to be sold off accounted for less than 1 percent of the combined entity’s revenues in India.
“Sun Pharma and Ranbaxy are looking forward to progressing towards the completion of the transaction and will comply with the conditions laid down by the CCI within the specified time,” they said.
Sun Pharma, India’s largest drugmaker by sales, last month said it was working on obtaining all the required regulatory approvals and expected to close the deal by December, but there could be “minor delays.”
Reporting by Zeba Siddiqui and Aman Shah in Mumbai; Editing by Sumeet Chatterjee/Keith Weir